Bladder cancer drugs market seen reaching $8.89 billion by 2030

5 hours ago
Bladder cancer drugs market seen reaching $8.89 billion by 2030
By AI, Created 15:00 UTC, Nov 20, 2026, AGP -

The Business Research Company says the global bladder cancer drugs market will grow from $4.82 billion in 2025 to $8.89 billion by 2030, with a 13.2% CAGR in the forecast period. Rising bladder cancer cases, wider screening and advances in personalized and immuno-oncology treatments are driving demand.

Why it matters: - The bladder cancer drugs market is expanding as more patients need treatment and drugmakers push more targeted therapies. - The projected growth points to stronger demand for oncology medicines, cancer screening and minimally invasive options. - North America led the market in 2025, while the Middle East is expected to be the fastest-growing region over the forecast period.

What happened: - The Business Research Company released its Global Bladder Cancer Drugs Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the market will rise from $4.82 billion in 2025 to $5.41 billion in 2026. - The report forecasts the market will reach $8.89 billion by 2030, implying a 13.2% CAGR over the forecast period. - The release was issued from London on Nov. 20, 2026. - A free sample report and the full market report are available online.

The details: - The market covers drugs used to treat bladder cancer, including urothelial carcinoma, squamous cell carcinoma, adenocarcinoma and other less common forms. - The report links historical growth to rising bladder cancer incidence, hospital-based oncology services, established chemotherapy, broad use of bacillus Calmette-Guérin therapy and better cancer detection. - The forecast period growth is tied to personalized oncology, immuno-oncology innovation, expanding healthcare infrastructure, broader cancer screening and demand for minimally invasive treatments. - The report says rising bladder cancer cases remain a major driver because the disease requires timely diagnosis, treatment to slow tumor growth and therapy to reduce relapse and metastasis. - The American Cancer Society estimated about 82,290 new U.S. bladder cancer cases in June 2023, including 62,420 in men and 19,870 in women. - The release says the broader pharmaceutical sector supports market growth through more oncology research, better production capacity and higher global demand for advanced cancer drugs. - Eurostat reported that in 2024, medicinal and pharmaceutical imports rose 0.5% from 2023, while exports increased 13.5%. - Eurostat said the trade surplus in the sector widened from $210 billion (€157 billion) to $260 billion (€194 billion). - The report adds new 2026 features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The market outlook suggests bladder cancer is moving deeper into the broader shift toward precision oncology, where drug selection is increasingly shaped by tumor type and treatment response. - The regional split also points to mature demand in North America and faster expansion in regions where healthcare access and cancer treatment capacity are still growing. - The report’s emphasis on screening and minimally invasive care suggests the market is being shaped by earlier diagnosis and treatment approaches that can broaden the pool of treatable patients.

What's next: - The market is expected to keep growing through 2030 as oncology pipelines, screening programs and healthcare infrastructure expand. - The Business Research Company is positioning its 2026 report set around forecasting tools and market analytics for buyers tracking category growth. - Companies and investors can access more information through the report pages and the company’s published contact channels.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

US National Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

US National Times

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.